Skip to main content

Table 2 Prevalence (%) of metabolic syndrome components according to the SST poly-T repeat polymorphism genotype

From: Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome

  Genotypes
All subjects 13/13 13/14 13/15 13/16 p
n 913 69 571 172  
 Abdominal Obesity 58.3 65.2 59.5 69.8 0.032
 Hypertriglyceridemia 50.4 55.1 55.7 61.6 0.026
 Low HDL-C level 51.2 50.7 51.5 62.2 0.058
 Hypertension 33.6 23.2 39.2 42.4 0.005
 Hyperglycaemia 36.5 46.4 38.2 45.9 0.060
 Diagnosis of Metabolic Syndrome 46.8 47.8 49.6 61.6 0.005
Men
n 475 38 289 99  
 Abdominal Obesity 74.5 73.7 72.3 80.8 NS
 Hypertriglyceridemia 53.3 63.2 60.2 68.7 0.019
 Low HDL-C level 55.6 50.0 56.4 67.7 NS
 Hypertension 33.3 21.1 34.6 35.4 NS
 Hyperglycaemia 43.6 55.3 42.9 49.5 NS
 Diagnosis of Metabolic Syndrome 57.1 52.6 56.7 66.7 NS
Women
n 438 31 282 73  
 Abdominal Obesity 40.6 54.8 46.5 54.8 0.056
 Hypertriglyceridemia 47.3 45.2 51.1 52.1 NS
 Low HDL-C level 46.3 51.6 46.5 54.8 NS
 Hypertension 34.0 25.8 44.0 52.1 0.002
 Hyperglycaemia 28.8 35.5 33.3 41.1 NS
 Diagnosis of Metabolic Syndrome 35.6 41.9 42.2 54.8 0.013
  1. NS: p ≥ 0.1 Abdominal obesity = waist circumference > 102 cm in men or > 88 cm in women; Hypertriglyceridemia = TG > 1.7 mmol/L; Low HDL-C level = HDL-Cholesterol < 1.03 mmol/L in men or < 1.3 mmol/L in women; Hypertension = blood pressure ≥ 130 mmHg systolic blood pressure or ≥ 85 mmHg diastolic blood pressure or hypertensive treatment; Hyperglycaemia = fasting glucose > 5.6 mmol/L or drug treatment for elevated blood glucose
  2. Significant p-value are in bold